Skip to content
Menu

Wedbush Downgrades Aclaris Therapeutics to Neutral, Lowers Price Target to $3

Benzinga Newsdesk 1 day ago

Analyst RatingsNewsDowngradesPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Wedbush analyst Martin Fan downgrades Aclaris Therapeutics (NASDAQ:ACRS) from Outperform to Neutral and lowers the price target from $8 to $3.

Wedbush analyst Martin Fan downgrades Aclaris Therapeutics (NASDAQ:ACRS) from Outperform to Neutral and lowers the price target from $8 to $3.

Read at benzinga.com